Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: A case report and review of the literature

Tony Reiman MD, Charles A Butts MD FRCPC

Can J Gastroenterol Vol 15 No 1 January 2001

BRIEF COMMUNICATION

Upper GI bleeding due to metastatic breast cancer

CASE PRESENTATION: A 64-year-old woman with known metastatic lobular breast cancer presented with fever, epigastric pain, hematemesis and melena. A bleeding, ulcerated gastric metastasis was found and was treated with endoscopic therapy, omeprazole and hormonal therapy. The patient was alive and well 13 months later. The bleeding was probably precipitated by necrosis of the lesion during chemotherapy.

DISCUSSION: Gastrointestinal tract metastases from primary breast carcinoma are present in 14% to 35% of cases in autopsy series, with gastric involvement in 6% to 18% of cases. Recognized much less commonly during life than in autopsy studies, they can occur anywhere in the gut and can mimic virtually any gastrointestinal disorder. Endoscopy and barium studies facilitate diagnosis. Gastric lesions that have been noted include 'linitis plastica', nodules, polyps and ulcers. They are usually due to lobular breast carcinoma and resemble primary gastric carcinoma on microscopy. Reported cases of bleeding gastric metastases have been treated successfully with various local and systemic modalities. The median survival time of reviewed cases was four months from presentation (with a range of zero to 24 months).

CONCLUSIONS: Gastrointestinal metastasis is an underdiagnosed complication of breast cancer. Gastrointestinal bleeding from metastatic breast cancer is an uncommon presentation that is readily diagnosed and that can be treated successfully by endoscopic hemostatic therapy.

Key Words: Breast cancer; Gastrointestinal bleeding
Upper gastrointestinal bleeding is an uncommon manifestation of breast cancer. A case due to the presence of an ulcerated metastatic gastric nodule is presented. The literature on gastric metastases in breast cancer patients is also reviewed.

**CASE PRESENTATION**

A 64-year-old woman was diagnosed in 1985 with a 3 cm infiltrating lobular carcinoma of the right breast (Figure 1). Estrogen and progesterone receptors were present. The patient underwent a modified radical mastectomy and axillary node dissection. Four of 11 axillary nodes were positive for metastatic disease. She was treated for one year with adjuvant chemotherapy.

Between 1990 and 1995, the patient developed metastatic disease in the lymph nodes, bones and skin. She was treated with tamoxifen and palliative radiotherapy. In 1997, multiple symptomatic liver metastases were found on a computed tomography scan of the abdomen. She had a minor response to anthracycline-based chemotherapy. Second-line hormonal therapy was then instituted but was discontinued within two months because of disease progression in the liver. An indwelling central venous catheter was inserted, and docetaxel chemotherapy was started in December 1997. Oral warfarin (1 mg daily) was prescribed to prevent catheter-associated thrombosis.

In January 1998, the patient developed a fever with no identifiable cause. It was thought to be due to the malignancy. She was given naproxen for symptomatic relief but stopped taking it after three days because the fever had resolved.

The patient presented in February 1998 with a seven-day history of nausea, anorexia, mild epigastric pain and malaise. Five days before presentation she had an episode of hematemesis followed by daily melena stools. She had another milder episode of hematemesis on the day of presentation and reported lightheadedness when standing.

Physical examination revealed conjunctival pallor. The patient's heart rate was normal; her blood pressure was 130/80 mmHg supine and 120/80 mmHg standing. There was mild epigastric tenderness, but no distention or peritoneal irritation was detected. The hemoglobin level was 78 g/L; three weeks previously, it had been stable at 106 g/L. The platelet count, prothrombin time and partial thromboplastin time were all normal.

The patient was admitted to hospital, and intravenous normal saline was given. Warfarin was discontinued. Two units of packed red blood cells were transfused. Gastroscopy was performed, revealing an ulcer on the anterior wall of the stomach measuring 1.5 cm. A blood vessel was visible in the centre of the ulcer. Pooled blood had clotted in the stomach. Five millilitres of 1:10,000 adrenaline were injected into the ulcer, and the visible vessel was electrically cauterized. Oral omeprazole (20 mg twice daily) was started.

The patient's melena subsided, and her hemoglobin level stabilized at 93 g/L. Repeat endoscopy four days later showed a healing ulcer with a clean base and no blood in the stomach. The esophagus, the rest of the stomach and the duodenum were all normal in appearance. Four quadrant biopsies of the ulcer edges were obtained. Cultures and microscopic examination of the gastric mucosa for *Helicobacter pylori* were negative.

The pathology slides of the gastric lesion showed infiltrating malignant cells forming single-file strands within the gastric lamina propria, with some associated inflammation and necrosis. Immunoperoxidase staining for estrogen receptors was strongly positive (Figure 2). The microscopic appearance and the estrogen receptor staining were most consistent with metastatic lobular breast cancer. Biopsies of a separate area of the stomach wall showed active gastritis but no evidence of malignancy.

After seven days in hospital, the patient was discharged with a diagnosis of lobular breast carcinoma metastatic to the stomach. Chemotherapy was withheld, and third-line
hormonal therapy was instituted. It was thought that the chemotherapy contributed to necrosis of the stomach lesion, leading to bleeding.

Follow-up endoscopy two months later showed only some residual scarring in the area of the previous ulcer. Biopsies of the area were negative for malignancy. Omeprazole was discontinued.

She subsequently required further chemotherapy and remained stable on fourth-line hormonal therapy. No further evidence of gastrointestinal bleeding had developed 13 months after the original bleed.

**DISCUSSION**

Gastrointestinal bleeding is an uncommonly reported manifestation of breast cancer. There are several such reports in the literature (1-11), but large series of breast cancer patients contain only rare cases (12-18). Causes of gastrointestinal bleeding in patients with breast cancer include esophageal varices due to liver metastases (8-11), bleeding esophageal (9), gastric (2,6,7) or colonic metastases (4), and acquired circulating anticoagulants (10). These diagnoses require consideration, along with the benign causes of gastrointestinal bleeding, such as peptic ulcer disease, gastritis and Mallory-Weiss tears.

Breast cancer has been found in virtually every location along the gastrointestinal tract, from mouth to anus (4,19). Any gastrointestinal symptom or sign seems to be reproducible by breast cancer. Esophageal stricture, achalasia, bowel obstruction or perforation, biliary tract or gallbladder disease, ileitis, pancolitis, appendicitis and peritoneal carcinomatosis have all been described (4,20-22).

Breast cancer is one of the major causes of gastrointestinal metastases. In an autopsy series of patients with gastric metastases, the majority of cases (excluding lymphomas) arose in patients with melanoma, breast carcinoma or lung carcinoma (13,23-25). Autopsy series in patients with breast cancer show a prevalence of metastases to the gastrointestinal tract of 14% to 35%, excluding serosal and liver disease (12,16,26,27). Series that reviewed gastric metastases, in particular, found a prevalence of 6% to 18% (5,15,16,27,28). These patients usually had widely disseminated breast cancer.

Gastric metastases are detected during life much less commonly than in autopsy studies, although they are occasionally the first sign of dissemination of breast cancer (3,29). Case series of symptomatic gastric metastases suggest that one to two cases per year are seen in breast cancer referral centres (1,14,17,30).

There are no specific symptoms of gastric metastases. The most frequent symptoms are nausea, vomiting and epigastric pain. Anorexia, weight loss, dysphagia, melena and hematemesis have all been reported. Iron deficiency anemia and guaiac-positive stools may also be presenting features (17,19).

Given the low prevalence of gastrointestinal metastases, most patients with breast cancer who present with these findings would be expected to have benign disease as the cause. This hypothesis is supported by a published series of 118 patients with breast cancer who were referred for endoscopy (31).

Seven cases of metastatic esophageal stenosis were found among the 39% of cases in which pathological findings had been detected. The majority of positive endoscopies revealed either benign ulceration or esophagitis.

Visualization of the stomach in patients with gastric metastases from breast cancer may reveal any of several morphologies. The most common is a ‘linitis plastica’ appearance due to diffuse intramural infiltration of the stomach with the tumour (1,2,19,28,30). This is characterized by a narrowing of the stomach lumen, rigidity and diminished peristalsis (19). This narrowing is seen much more readily with barium studies than with endoscopy (32). Other appearances of gastric metastases include nodular or polypoid lesions and ulcerated lesions (17,19,30). Among the cases reviewed that reported morphological findings, there was one published series of 31 cases of linitis plastica (1). Features of linitis plastica were reported in an additional 28 of 47 cases (60%) with published morphological findings. Prior reviews have found that 43% to 73% of patients with gastric metastases from breast cancer present with linitis plastica (19,30).

Although ductal carcinoma is by far the most common primary breast tumour (33), lobular carcinoma is the predominant histology in gastric metastases (3,17,30). Among the cases reviewed, 55 of 64 cases (86%) in which histology was reported showed lobular carcinoma. Several large clinical and autopsy series (34-40) have examined the differences in the pattern of metastases of ductal and lobular breast cancer. A significantly higher prevalence of gastrointestinal and peritoneal metastases with lobular breast cancer has been found repeatedly (34-39). Even in cases in which the primary tumour is of mixed histology, it is the lobular component that tends to appear in the stomach (1,29). It has been suggested that ductal carcinomas tend to produce nodular stomach lesions, while lobular carcinomas tend to cause more diffuse disease (1), but the present case shows that this suggestion is not always true.

The pathology of gastric metastases from breast cancer suggests a hematogenous route of spreading (2,3,19,41). The lesions originate in the gastric submucosa with subsequent extension into the mucosa or serosa. Signet ring cells are frequently seen (23,42). Lobular breast cancer cells tend to form strands rather than glandular structures and can be difficult to distinguish from primary gastric carcinomas. Helpful distinguishing features for metastatic disease include the absence of a smooth transition to normal mucosa, a similarity to the histology of the primary tumour, and the presence of estrogen and/or progesterone receptors (2,3,42). However, none of these features are pathognomonic for breast cancer metastases nor do they rule out primary gastric carcinoma.

The management of gastric metastases has varied. Successes have been documented with several approaches, including surgery, endoscopy, radiotherapy, chemotherapy and hormonal therapy (3,16,17,29). Local therapy, such as surgery, to control bleeding has allowed longevity, even in patients with widespread disease (16). Most reports on the surgical management of gastric metastases predate the era of
therapeutic endoscopy or effective systemic therapies for metastatic breast cancer (6,16,41). More recent reports usually feature systemic therapy, radiotherapy and/or endoscopy as the treatments of choice (7,17,19).

Survival among reported cases has varied widely. Gastrointestinal bleeding has led to early death in some of the reported cases, but survival has extended up to 24 months beyond the diagnosis of bleeding in other cases (1-11). Among 13 cases of bleeding gastric metastases where such data were published, the median length of survival from the date of the bleeding was four months. Among 15 published cases of nonbleeding gastric metastases with survival data, as well as among the 28 pooled bleeding and nonbleeding cases, the median length of survival from diagnosis was seven months (the range was zero months to longer than 3.5 years).

In the present case, it appears that a temporal association existed between the administration of chemotherapy, and the subsequent ulceration and brisk bleeding of the gastric lesion. The concomitant use of naproxen and warfarin initially (and incorrectly) suggested a benign cause of the bleeding. The combination of local endoscopic therapy and a change in the systemic therapy was successful in preventing rebleeding. It is likely that the resolution of the lesion was in response to antineoplastic therapy, although the partial removal of the blood supply by electrocautery may have played a role. It is possible that the subsequent healing of the gastric mucosa was facilitated by the proton pump inhibitor.

A prolonged period of survival with good quality of life was achieved by the patient without long term omeprazole therapy. The likelihood of gastric recurrence is unknown but is probably high. Further studies on the role of gastric acidity in the pathogenesis of ulcerated gastric metastases would be helpful in clarifying the potential benefit of maintenance proton pump inhibitor therapy.

CONCLUSIONS

Gastrointestinal metastases are a common but underrecognized complication of breast cancer. Gastrointestinal metastases are usually due to lobular rather than ductal carcinoma and often occur in the setting of widely disseminated disease. The clinical presentation is nonspecific and likely is often misdiagnosed as cancer cachexia, therapeutic toxicity or metabolic derangement. Visualization of the gastrointestinal tract with endoscopy and/or barium studies is helpful, and biopsies can establish the diagnosis.

Gastrointestinal bleeding in the breast cancer patient must prompt the clinician to consider metastatic disease as the cause. Bleeding gastroduodenal ulcers in the breast cancer patient may be due to metastatic, rather than peptic, disease. Treatment can be multimodal and must be individualized. Many patients with metastatic breast cancer, such as the one presented in this report, can have long term survival with good quality of life. For such patients, the aggressive management of complications such as gastrointestinal bleeding is clearly indicated.

ACKNOWLEDGEMENTS: This patient was treated at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. The authors are indebted to the gastroenterology consult team at the Queen Elizabeth II Health Sciences Centre, headed by Dr J Love, who performed the endoscopic procedures necessary for the diagnosis and treatment of this patient. Dr D Murphy, pathologist at the Queen Elizabeth II Health Sciences Centre, interpreted the pathological specimens and provided the photomicrographs.

REFERENCES


